OS Therapies Incorporated (OSTX)
NYSEAMERICAN: OSTX · Real-Time Price · USD
1.520
-0.030 (-1.94%)
At close: Mar 12, 2026, 4:00 PM EDT
1.560
+0.040 (2.63%)
Pre-market: Mar 13, 2026, 4:52 AM EDT
OS Therapies Employees
As of December 31, 2024, OS Therapies had 5 total employees, including 4 full-time and 1 part-time employees. The number of employees increased by 1 or 25.00% compared to the previous year.
Employees
5
Change
1
Growth
25.00%
Revenue / Employee
n/a
Profits / Employee
-$4,051,244
Market Cap
53.53M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 5 | 1 | 25.00% | 4 | 1 |
| Mar 31, 2024 | 4 | 0 | - | 3 | 1 |
| Sep 30, 2023 | 4 | 0 | - | 3 | 1 |
| Mar 31, 2023 | 4 | - | - | 3 | 1 |
| Dec 31, 2022 | 4 | - | - | 3 | 1 |
Related Stocks
| Company Name | Employees |
|---|---|
| Metagenomi Therapeutics | 124 |
| Acrivon Therapeutics | 78 |
| Kezar Life Sciences | 55 |
| Atara Biotherapeutics | 38 |
| Plus Therapeutics | 21 |
| Edesa Biotech | 17 |
| Lipocine | 16 |
| Rallybio | 15 |
OSTX News
- 3 days ago - OS Therapies Announces FDA OST-HER2 Type D Meeting Elevated to Type B Pre-BLA Meeting - Newsfile Corp
- 23 days ago - OS Therapies Discloses 2026 Timeline For Lead Drug Regulatory Filings - Benzinga
- 23 days ago - OS Therapies Provides Global Regulatory Update for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metstatic Osteosarcoma - Newsfile Corp
- 5 weeks ago - OS Therapies Applauds Reauthorization of Pediatric Priority Review Voucher Program to Advance Breakthrough Osteosarcoma Immunotherapies - Newsfile Corp
- 5 weeks ago - OS Therapies Initiates US FDA BLA Filing for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma - Newsfile Corp
- 2 months ago - OS Therapies Bone Cancer Trial Data Strengthens FDA Case - Benzinga
- 2 months ago - OS Therapies Announces Positive Biomarker Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma - Newsfile Corp
- 2 months ago - OS Therapies Announces Filing Form S-1 of OS Animal Health Subsidiary - Newsfile Corp